NO914002D0 - Fremgangsmaate for fremstilling av mettede hydroxyalkylkinolinsyrer - Google Patents

Fremgangsmaate for fremstilling av mettede hydroxyalkylkinolinsyrer

Info

Publication number
NO914002D0
NO914002D0 NO914002A NO914002A NO914002D0 NO 914002 D0 NO914002 D0 NO 914002D0 NO 914002 A NO914002 A NO 914002A NO 914002 A NO914002 A NO 914002A NO 914002 D0 NO914002 D0 NO 914002D0
Authority
NO
Norway
Prior art keywords
hydroxylkylqinolic
acids
preparing saturated
saturated
preparing
Prior art date
Application number
NO914002A
Other languages
English (en)
Other versions
NO914002L (no
Inventor
Michel L Belley
Serge Leger
Patrick Roy
Yi Bin Xiang
Marc Labelle
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of NO914002D0 publication Critical patent/NO914002D0/no
Publication of NO914002L publication Critical patent/NO914002L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
NO91914002A 1990-10-12 1991-10-11 Fremgangsmaate for fremstilling av mettede hydroxyalkylkinolinsyrer som leukotrienantagonister NO914002L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59684490A 1990-10-12 1990-10-12

Publications (2)

Publication Number Publication Date
NO914002D0 true NO914002D0 (no) 1991-10-11
NO914002L NO914002L (no) 1992-04-13

Family

ID=24388953

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91914002A NO914002L (no) 1990-10-12 1991-10-11 Fremgangsmaate for fremstilling av mettede hydroxyalkylkinolinsyrer som leukotrienantagonister

Country Status (16)

Country Link
US (1) US5428033A (no)
EP (1) EP0480716A1 (no)
JP (1) JP2538155B2 (no)
KR (1) KR920008004A (no)
CN (1) CN1061408A (no)
AU (1) AU639611B2 (no)
CA (1) CA2053216C (no)
CS (1) CS309391A3 (no)
FI (1) FI914797A (no)
HU (1) HUT61980A (no)
IE (1) IE913611A1 (no)
IL (1) IL99725A0 (no)
MX (1) MX9101557A (no)
NO (1) NO914002L (no)
PT (1) PT99212B (no)
ZA (1) ZA918120B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
CA2111372C (en) * 1992-12-22 2007-01-16 Robert N. Young Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5438141A (en) * 1993-05-21 1995-08-01 Merck Frosst Canada, Inc. Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
ES2080656B1 (es) * 1993-07-19 1996-10-16 Merck Frosst Canada Inc Acidos de hidroxialquilquinolina fluorados como antagonistas del leucotrieno.
TW416948B (en) * 1993-12-28 2001-01-01 Merck & Co Inc Process for the preparation of leukotriene antagonists
US5750539A (en) * 1995-06-07 1998-05-12 Merck Frosst Canada Heteroaryl diol acids as leukotriene antagonists
US6696466B1 (en) 2000-09-07 2004-02-24 Leslie Joe Dunaway Methods of treating select neuronal inflammatory disorders using hydroxyalkylquinolines
CA2735267C (en) * 2001-01-26 2013-05-07 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
US7279477B2 (en) * 2001-01-26 2007-10-09 Chugai Seiyaku Kabushiki Kaisha Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
JP4503232B2 (ja) 2001-01-26 2010-07-14 中外製薬株式会社 マロニル−ＣｏＡ脱炭酸酵素阻害剤を用いた疾患の治療法
US7709510B2 (en) * 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
PT1370260E (pt) 2001-02-20 2011-02-01 Chugai Pharmaceutical Co Ltd Azóis como inibidores da malonil-coa-descarboxilase úteis como moduladores metabólicos
EP1653944B1 (en) * 2003-08-01 2010-11-10 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
CA2533749C (en) * 2003-08-01 2012-07-10 Chugai Seiyaku Kabushiki Kaisha Piperidine compounds useful as malonyl-coa decarboxylase inhibitors
US7285562B2 (en) * 2003-08-01 2007-10-23 Chugai Seiyaku Kabushiki Kaisha Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors
EP1658071B1 (en) * 2003-08-01 2008-09-10 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azole compounds useful as malonyl-coa decarboxylase inhibitors
IL174758A (en) * 2003-10-10 2012-09-24 Synthon Bv Crystalline form of montelukast, pharmaceutical composition comprising it, process for the preparation thereof and uses thereof as a medicament
WO2005075427A2 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
JP2007532686A (ja) * 2004-04-21 2007-11-15 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストナトリウムを調製する方法
CN101213177A (zh) * 2005-07-05 2008-07-02 特瓦制药工业有限公司 孟鲁司特的纯化
AR056815A1 (es) * 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
WO2009001374A2 (en) * 2007-06-25 2008-12-31 Aptuit Laurus Pvt Ltd Preparation of ethyl-3'-[((7-chloro-2-quinolinyl)ethenyl)phenyl]-3-oxopropanoate, a key intermediate for montelukast sodium
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
BR112014001760A2 (pt) * 2011-07-26 2017-03-07 Sun Pharma Advanced Res Co Ltd antagonistas de leucotrieno cisteínico
CN113613657A (zh) * 2019-01-10 2021-11-05 江阴优培尔康药业有限公司 含有白三烯受体拮抗剂的新型配制品

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1144905A (en) 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4325961A (en) 1977-06-01 1982-04-20 Merck & Co., Inc. Fluorinated amino acids
PT68303A (en) 1977-07-26 1978-08-01 Merck & Co Inc Process for the preparation of dibenzo/b,f/thiepin
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
PH16099A (en) 1979-03-06 1983-06-24 Yamanouchi Pharma Co Ltd Guanidinothiazole compounds,process for preparing them and medical composition containing them
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
GB2058785B (en) 1979-09-05 1983-05-25 Glaxo Group Ltd Phenol derivatives
US4237160A (en) 1979-11-27 1980-12-02 Merck Sharp & Dohme (I.A.) Corp. 3-Hydroxymethyldibenzo[b,f]thiepins as prostaglandin antagonists
DE3175201D1 (en) 1980-04-30 1986-10-02 Merck & Co Inc Aminothiadiazoles as gastric secretion inhibitors
US4394508A (en) 1980-06-07 1983-07-19 Bristol-Myers Company Chemical compounds
EP0056172B1 (en) 1981-01-09 1985-04-03 FISONS plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
EP0061800B1 (en) 1981-03-24 1985-08-28 FISONS plc Anti srs-a carboxylic acid derivatives, processes for their production and pharmaceutical formulations containing them
NZ205559A (en) 1982-09-23 1987-08-31 Merck Frosst Canada Inc Leukotriene antagonists, pharmaceutical compositions, and intermediates
DE3366107D1 (en) 1982-09-30 1986-10-16 Merck Frosst Canada Inc Leukotriene antagonists, their production, and compositions containing them
NZ206795A (en) 1983-01-21 1987-08-31 Merck Frosst Canada Inc Phenothiazines, analogues and pharmaceutical compositions
EP0136893B1 (en) 1983-10-05 1989-08-16 Merck Frosst Canada Inc. Benzo[a]phenothiazines and hydro-derivatives and pharmaceutical compositions containing them
EP0138481B1 (en) 1983-10-05 1991-06-26 Merck Frosst Canada Inc. Leukotriene biosynthesis inhibitors
ES8602818A1 (es) 1983-10-31 1985-12-01 Merck Frosst Canada Inc Una composicion farmaceutica
IE861607L (en) * 1985-06-18 1986-12-18 Bunce Roger A 2-substituted quinolines
IE59889B1 (en) 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
US4851409A (en) 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
EP0271287A3 (en) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Quinoline dioic acids and amides
DE3700732A1 (de) * 1987-01-13 1988-07-21 Boehringer Mannheim Gmbh Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920131A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
IL88433A0 (en) * 1987-11-25 1989-06-30 Merck Frosst Canada Inc Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
US5104882A (en) * 1987-11-25 1992-04-14 Merck Frosst Canada, Inc. Diarylstrylquinoline diacids and pharmaceutical compositions thereof
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
IL99725A0 (en) 1992-08-18
FI914797A0 (fi) 1991-10-11
CA2053216C (en) 2003-04-08
US5428033A (en) 1995-06-27
PT99212B (pt) 1999-04-30
EP0480716A1 (en) 1992-04-15
HUT61980A (en) 1993-03-29
NO914002L (no) 1992-04-13
MX9101557A (es) 1994-05-31
CN1061408A (zh) 1992-05-27
IE913611A1 (en) 1992-04-22
PT99212A (pt) 1992-09-30
AU639611B2 (en) 1993-07-29
AU8579691A (en) 1992-04-16
ZA918120B (en) 1992-06-24
CA2053216A1 (en) 1992-04-13
CS309391A3 (en) 1992-05-13
HU913216D0 (en) 1992-01-28
FI914797A (fi) 1992-04-13
KR920008004A (ko) 1992-05-27
JPH06206868A (ja) 1994-07-26
JP2538155B2 (ja) 1996-09-25

Similar Documents

Publication Publication Date Title
NO914002D0 (no) Fremgangsmaate for fremstilling av mettede hydroxyalkylkinolinsyrer
TR25002A (tr) Kristalik natrinyumsilikatlarin hazirlanis yöntemi
DK293590A (da) Fermenteringsfremgangsmaade til fremstilling af carboxylsyrer
NO930525D0 (no) Framgangsmaate for utvikling av umettede fettsyrer
FI95036B (fi) Tieno-triatsolo-diatsepiinijohdosten valmistusmenetelmä
KR860005834A (ko) N-보호된-α-L-아스파르틸-L-페닐알라닌 메틸 에스테르의 제조방법
EE03027B1 (et) Meetod 8-klorokinolooni derivaatide valmistamiseks
NO912303L (no) Fremgangsmaate for fremstilling av en amorf form av gemfibrozil
BR9102112A (pt) Metodo de fabricacao de ziperes
DE69118430D1 (de) Verfahren zur Herstellung von Polyanilinderivaten
LV10119A (lv) Lizocima dimeru iegusanas metode
DE69216144D1 (de) Verfahren zur Herstellung von Alpha-Aspartyl-Phenylalanin-Methylester
DE69211756D1 (de) Verfahren zur Herstellung von alpha-L-aspartyl-L-phenylalaninmethylester
DE69216125D1 (de) Verfahren zur Herstellung von 2-Exo-methylenpenam-Derivaten
DK358288D0 (da) Fremgangsmaade til fremstilling af 2-arylthiobenzoesyrer
FI91069B (fi) Menetelmä 5-C-hydroksimetyylialdoheksoosipohjaisten yhdisteiden valmistamiseksi
NO178577C (no) Fremgangsmåte til fremstilling av cefalosporin
NO177307C (no) Fremgangsmåte for fremstilling av 2-diazo-3-trisubstituerte silyloksy-3-butenoatestere
FR2632303B1 (fr) Procede de preparation du 3-aminocrotonate de methyle
KR950700320A (ko) 3-아실안드로스타디엔을 제조하는 방법(Process of preparing 3-acylandrostadienes)
KR950700319A (ko) 3-카르보닐안드로스타디엔 17-카르복스아미드를 제조하는 방법(Process of preparing 3-carbonylandrostadiene 17-carboxamides)
DE59208718D1 (de) Verfahren zur Herstellung von Imidazothiazolon-Derivaten
BG96675A (bg) Метод за дехидрогениране/дехидроциклизиране на алифатни съединения
NO174196C (no) Fremgangsmåte for fremstilling av omega-decenol
DE59107283D1 (de) Verfahren zur Herstellung von racemischen Pilosinin-Derivaten